Dunkin parent in talks with 2 rivals

BY NAOMI ASKI

Red Dome PLC, the British parent of Dunkin' Brands Inc., will sell its North American business to a rival or retain it, in a deal that would have major implications for the companies involved.

Dunkin Brands is the parent of Dunkin' Donuts, Baskin-Robbins and Togo's, and the deal would include Dunkin' Donuts and Togo's. The company also owns several other brands, including Baskin-Robbins and Seattle's Best.

Dunkin Brands is the world's largest coffee-and-doughnut franchise, with more than 10,000 stores in over 50 countries. The company has been in talks with several potential buyers, including a private equity firm, for several months.

The deal could be completed by the end of the year, according to sources familiar with the discussions. Dunkin Brands has already filed for a rights offering, which will provide it with additional capital to fund growth.

A deal of this size would be a major milestone for the company, which has been looking to expand its international presence in recent years.

By Ross Kerber

A medical study published today offers intriguing evidence that drugs from a Novel oral therapeutics company are effective for treating alcohol dependency.

The study, led by Dr. John Smith of the University of California, San Francisco, showed that a new drug, named Vivitrex, reduced binge drinking in alcohol-dependent patients.

Vivitrex is a novel drug that works by inhibiting the activity of a certain neurotransmitter, which is responsible for driving alcohol consumption.

The results of the study were published in the Journal of Clinical Pharmacology, and they suggest that Vivitrex could be a potential treatment for alcohol dependence.

The study involved 100 patients, and it showed that those who were treated with Vivitrex had a significant reduction in their binge drinking episodes.

The study was sponsored by a major pharmaceutical company, and it was funded by a grant from the National Institute on Alcohol Abuse and Alcoholism.

The findings of the study have been widely reported in the media, and they have generated a lot of interest among researchers and clinicians.

By Charles Stein

New york city's largest private equity firm, The Carlyle Group, has announced that it plans to raise a $7.5 billion fund to invest in buyout opportunities.

The fund, which will be called Carlyle X, is expected to be one of the largest funds ever raised in the buyout industry.

The Carlyle Group has a long history of successful investments, and it has been a leader in the private equity industry for many years.

By Ross Kerber

A medical study published today offers intriguing evidence that drugs from a Novel oral therapeutics company are effective for treating alcohol dependency.

The study, led by Dr. John Smith of the University of California, San Francisco, showed that a new drug, named Vivitrex, reduced binge drinking in alcohol-dependent patients.

Vivitrex is a novel drug that works by inhibiting the activity of a certain neurotransmitter, which is responsible for driving alcohol consumption.

The results of the study were published in the Journal of Clinical Pharmacology, and they suggest that Vivitrex could be a potential treatment for alcohol dependence.

The study involved 100 patients, and it showed that those who were treated with Vivitrex had a significant reduction in their binge drinking episodes.

The study was sponsored by a major pharmaceutical company, and it was funded by a grant from the National Institute on Alcohol Abuse and Alcoholism.

The findings of the study have been widely reported in the media, and they have generated a lot of interest among researchers and clinicians.

By Charles Stein

New york city's largest private equity firm, The Carlyle Group, has announced that it plans to raise a $7.5 billion fund to invest in buyout opportunities.

The fund, which will be called Carlyle X, is expected to be one of the largest funds ever raised in the buyout industry.

The Carlyle Group has a long history of successful investments, and it has been a leader in the private equity industry for many years.

By Ross Kerber

A medical study published today offers intriguing evidence that drugs from a Novel oral therapeutics company are effective for treating alcohol dependency.

The study, led by Dr. John Smith of the University of California, San Francisco, showed that a new drug, named Vivitrex, reduced binge drinking in alcohol-dependent patients.

Vivitrex is a novel drug that works by inhibiting the activity of a certain neurotransmitter, which is responsible for driving alcohol consumption.

The results of the study were published in the Journal of Clinical Pharmacology, and they suggest that Vivitrex could be a potential treatment for alcohol dependence.

The study involved 100 patients, and it showed that those who were treated with Vivitrex had a significant reduction in their binge drinking episodes.

The study was sponsored by a major pharmaceutical company, and it was funded by a grant from the National Institute on Alcohol Abuse and Alcoholism.

The findings of the study have been widely reported in the media, and they have generated a lot of interest among researchers and clinicians.

By Charles Stein

New york city's largest private equity firm, The Carlyle Group, has announced that it plans to raise a $7.5 billion fund to invest in buyout opportunities.

The fund, which will be called Carlyle X, is expected to be one of the largest funds ever raised in the buyout industry.

The Carlyle Group has a long history of successful investments, and it has been a leader in the private equity industry for many years.